Please assess the completion status of the following clinical trial:

Trial Title: Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male, age older than 22 and younger than 75 years of age~2. The patient should be a candidate for surgical treatment of bladder outlet obstruction.~3. Patients with BPH and surgical indication (refractory to medical treatment, refractory or recurrent urinary retention, recurrent haematuria, bladder stones, recurrent infections, hydronephrosis)~4. Prostate volume ˃30 and ≤80 ml~5. PSA \<4 ng/ml in patients above 55 years old and a prostate cancer risk less than 35%. (Prostate cancer risk calculator).~6. IPSS ≥8 (moderate to severe)~7. Indications for TURIS~8. maximum urinary flow (Qmax) \<10ml/second~9. A written informed consent signed by the patient (including patient's agreement to randomization and treatment).~Exclusion Criteria:~1. Patients under anti-inflammatory or steroid therapy~2. Patients under anti-coagulation at a level that could be exposed to a very high risk of complications based on a comprehensive pre-operatory evaluation.~3. Renal insufficiency Serum creatinine (Scr) \>1.5 x upper limit of normal (ULN); AST and ALT\>2.5 x ULN;Total bilirubin \>1.5 x ULN~4. Previous neurogenic lower urinary tract dysfunction.~5. Patients with urethral strictures~6. Severe pulmonary disease and cardio-vascular disorder 、Coagulopathy，and contraindications to anesthesia and surgery.~7. Concurrent participation in any other clinical study~8. Any of the following within the 12 months prior to study: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism.~9. Previous bladder outlet surgery.~10. A clinically significant acute illness.~11. Intake of medication in which the principle investigator considers to preclude enrollment into the trial.~12. Known disease of the central or peripheral nervous system.~13. Any clinical evidence of carcinoma of the prostate.~14. HIV positive or any other immunosuppressive disorder.~15. Psychological/psychiatric disease /Known cognitive disorder.

- Gender: MALE
- Minimum Age: 22 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TVERP (Type: ACTIVE_COMPARATOR): None
- TURis (Type: ACTIVE_COMPARATOR): None
- HoLEP (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).